Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이경은 | * |
dc.date.accessioned | 2016-08-29T12:08:43Z | - |
dc.date.available | 2016-08-29T12:08:43Z | - |
dc.date.issued | 2016 | * |
dc.identifier.issn | 1598-2998 | * |
dc.identifier.other | OAK-18482 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/231497 | - |
dc.description.abstract | Purpose While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall survival (OS) benefit was not found in Asian and diffuse-type cancer patients. The aim of the study is to investigate predictive markers for trastuzumab-based chemotherapy. Materials and Methods Data of patients with HER2-positive gastric cancer treated with trastuzumab-based chemotherapy were analyzed retrospectively. Results A total of 168 Asian patients were included. The median age was 60 years (range, 27 to 85 years) and the male:female ratio was 118 (70.2%):50 (29.8%). Fourteen (8.3%), 63 (37.5%), 75 (44.6%), and 11 (6.5%) patients had well, moderately, poorly-differentiated tubular adenocarcinoma and signet ring cell carcinoma, respectively. With 14 complete responses and 73 partial responses, the response rate was 50.6%. The median progression-free survival (PFS) was 10.2 months (95% confidence interval [CI], 8.7 to 11.7), and the median OS was 18.5 months (95% CI, 16.4 to 50.6). Next, we investigated the effect of poorly-differentiated histology (PDH, poorly-differentiated tubular adenocarcinoma+signet ring cell carcinoma) on clinical outcomes. The median PFS (8.9 months vs. 11.5 months, p=0.16) was slightly inferior in PDH patients, and the median OS was significantly shorter in PDH patients (14.6 months vs. 19.0 months, p=0.025). Conclusion While subset analysis of the ToGA trial demonstrated that trastuzumab-based chemotherapy may not be beneficial for Asians and patients with PDH, our data may suggest that even in Asian patients and patients with PDH, trastuzumab-based chemotherapy could be associated with improved clinical outcomes in patients with HER2-positive gastric cancer. © 2016 by the Korean Cancer Association. | * |
dc.language | English | * |
dc.publisher | Korean Cancer Association | * |
dc.subject | ErbB-2 receptor | * |
dc.subject | Ethnic groups | * |
dc.subject | Histology | * |
dc.subject | Stomach neoplasms | * |
dc.subject | Trastuzumab | * |
dc.title | A retrospective analysis for patients with HER2-positive gastric cancer who were treated with trastuzumab-based chemotherapy: In the perspectives of ethnicity and histology | * |
dc.type | Article | * |
dc.relation.issue | 2 | * |
dc.relation.volume | 48 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.index | KCI | * |
dc.relation.startpage | 553 | * |
dc.relation.lastpage | 560 | * |
dc.relation.journaltitle | Cancer Research and Treatment | * |
dc.identifier.doi | 10.4143/crt.2015.155 | * |
dc.identifier.wosid | WOS:000374197200015 | * |
dc.identifier.scopusid | 2-s2.0-84963894352 | * |
dc.author.google | Yi J.H. | * |
dc.author.google | Kang J.H. | * |
dc.author.google | Hwang I.G. | * |
dc.author.google | Ahn H.K. | * |
dc.author.google | Baek H.J. | * |
dc.author.google | Lee S.I. | * |
dc.author.google | Lim D.H. | * |
dc.author.google | Won Y.-W. | * |
dc.author.google | Ji J.H. | * |
dc.author.google | Kim H.S. | * |
dc.author.google | Rha S.Y. | * |
dc.author.google | Oh S.Y. | * |
dc.author.google | Lee K.E. | * |
dc.author.google | Lim T. | * |
dc.author.google | Maeng C.H. | * |
dc.author.google | Kim M.J. | * |
dc.author.google | Kim S.T. | * |
dc.author.google | Lee J. | * |
dc.author.google | Park J.O. | * |
dc.author.google | Park Y.S. | * |
dc.author.google | Lim H.Y. | * |
dc.author.google | Kang W.K. | * |
dc.author.google | Park S.H. | * |
dc.contributor.scopusid | 이경은(7501517217;58364338700) | * |
dc.date.modifydate | 20240123091958 | * |